Impact of supplementation with vitamins B₆, B₁₂, and/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impairment: A systematic review

Gloria Olaso-Gonzalez¹ | Marco Inzitari²,³ | Giuseppe Bellelli⁴ | Alessandro Morandi²,⁵ | Núria Barcons⁶ | José Viña¹

¹Department of Physiology, Faculty of Medicine, Universitat de València, Valencia, Spain  
²REFiT Barcelona Research Group, Parc Sanitari Pere Virgili and Vall d'Hebrón Institute of Research, Barcelona, Spain  
³Department of Health Sciences, Universitat Oberta de Catalunya, Barcelona, Spain  
⁴School of Medicine and Surgery, University of Milano-Bicocca and Acute Geriatric Unit, San Gerardo Hospital, Monza, Italy  
⁵Department of Rehabilitation and Aged Care, Fondazione Teresa Camplani, Hospital Ancelle, Cremona, Italy  
⁶Medical Affairs, Nestlé Health Science, Vevey, Switzerland

Abstract

Hyperhomocysteinemia is an independent predictor of the risk for cognitive decline and may be a result of low levels of vitamins B₁₂, B₆, and folate. Previous findings suggest that adequate intake of these vitamins may reduce homocysteine levels. This review aimed to assess the effects of treatment with vitamins B₆, B₁₂, and/or folic acid in the homocysteine levels in patients with mild cognitive impairment (MCI). A systematic literature review was conducted in EMBASE, MEDLINE®, PsycINFO, and Cochrane Central Register of Controlled Trials. The research question was formulated using the Population, Intervention, Comparison, and Outcome (PICO) framework: in patients with MCI (P); what is the efficacy of vitamins B₆, B₁₂, and/or folic acid in the homocysteine levels in patients with mild cognitive impairment (MCI)? A systematic literature review was conducted in EMBASE, MEDLINE®, PsycINFO, and Cochrane Central Register of Controlled Trials. The research question was formulated using the Population, Intervention, Comparison, and Outcome (PICO) framework: in patients with MCI (P); what is the efficacy of vitamins B₆, B₁₂, and/or folic acid intake (I); compared with baseline values, and/or compared with controls (C); in reducing homocysteine levels from baseline (O). A total of eight primary studies with a total of 1,140 participants were included in the review. Four were randomized controlled trials, one was a quasi-controlled trial, and three were observational studies. All studies included folic acid in their intervention, seven vitamin B₁₂, and four vitamin B₆. Mean (SD) length of the intervention period was 18.8 (19.3) months, ranging from 1 to

Abbreviations: AD, Alzheimer disease; BHMT, betaine-homocysteine methyltransferase; C, comparison; CBS, cystathionine β-synthase; CT, controlled trial; GPx, glutathione peroxidase; I, intervention; m, month; MCI, mild cognitive impairment; MMSE, mini-mental state examination; MTR, methionine synthase; NR, not reported; GSH, glutathione; GST, glutathione reductase and glutathione s-transferase; O, outcome; P, population; PICO, population, intervention, comparison, and outcome; PRISMA, preferred reporting items for systematic reviews and meta-analyses; RCT, randomized controlled trial; ROB 2, Cochrane risk-of-bias version 2; ROS, reactive oxygen species; tHcy, total homocysteine concentration; vit, vitamin.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2021 The Authors. IUBMB Life published by Wiley Periodicals LLC on behalf of International Union of Biochemistry and Molecular Biology.
60 months. All studies showed a statistically significant decrease in homocysteine levels in groups treated with vitamins B6, B12, and/or folic acid compared to controls, with a mean decline of homocysteine concentration of 31.9% in the intervention arms whereas it increased by 0.7% in the control arm. This review identified evidence of a reduction of plasma homocysteine levels in MCI patients taking vitamins B6, B12, and/or folic acid supplements, with statistically significant declines being observed after 1 month of supplementation. Findings support that supplementation with these vitamins might be an option to reduce homocysteine levels in people with MCI and elevated plasma homocysteine.

**KEYWORDS**

folic acid, homocysteine, mild cognitive impairment, vitamin B6, vitamin B12

---

1 | **INTRODUCTION**

Mild cognitive impairment (MCI) is a condition that is prodromal to Alzheimer’s disease (AD) and marked by a subjective memory impairment and modest deficits in at least one of the following cognitive domains: executive function, memory, language, processing speed or attention.\(^1\) The main distinction between MCI and mild dementia is that the latter involves more than one cognitive domain and there is a substantial interference with daily activities, while MCI may affect only one cognitive domain and does not substantially interfere with daily activities.\(^2\) MCI is common among older people and its prevalence increases with age, being estimated that 6.7% of people aged 60–64 years old suffer from this condition, 8.4% of those aged 65–69, 10.1% of those aged 70–74, 14.8% of those aged 75–79, and 25.2% of those aged 80–84 years old.\(^3\) MCI patients are at high risk of progressing to dementia\(^2,4\) and around 50% of cases are estimated to progress to AD within 5 years.\(^1,4\) As such, early therapeutic interventions are required to prevent degenerative neurological damage.\(^5,6\)

Patients suffering from MCI have increased oxidative damage even before the onset of symptoms.\(^7\) Oxidative damage is caused by a high production of reactive oxygen species (ROS) that cannot be managed by antioxidant defenses. Glutathione-dependent enzymes such as glutathione peroxidase (GPx), glutathione reductase, and glutathione S-transferase (GST) are antioxidant enzymes responsible for controlling ROS.\(^8\) Cysteine is a major contributor to Glutathione (GSH) synthesis that can be obtained from the transsulfuration pathway from homocysteine to cysteine (Figure 1).

Homocysteine is also able to autoxidize in the presence of molecular oxygen and transition metal catalysts, promoting the formation of ROS such as hydrogen peroxide, hydroxyl, and thiol free radicals.\(^11,13\) (Figure 1). Plasma/serum total homocysteine concentration (tHcy) is the sum of homocysteine in all its three forms (protein-bound, free circulating disulfide, and sulfhydryl), and under conditions of maximal metabolic efficiency, tHcy levels of homocysteine range from 4 to 10 μmol/L.\(^10\) Elevated blood levels of homocysteine (hyperhomocysteinemia) may be defined as a tHcy level >15 μM, although there may also be increased risks for people with tHcy concentrations of 10–15 μM.\(^14\)

The normal functioning of the homocysteine metabolism is dependent on the adequate intake of three vitamins: vitamin B9 (folate/folic acid), vitamin B12 (cobalamin), and vitamin B6 (pyridoxal phosphate), and a low level of these vitamins is a key cause of hyperhomocysteinemia.\(^10,15\) (Figure 1).

Strategies aimed at improving nutrition are increasingly being studied, in light of evidence that B vitamin deficiencies may contribute to the pathogenesis of cognitive impairment, through elevated blood levels of homocysteine.\(^16–20\) Moderately elevated levels of tHcy are common in the population and increase with aging.\(^21–23\) Increased prevalence of hyperhomocysteinemia is observed both in non-institutionalized elderly and in those living in care-facility homes, population where deficits of vitamin B12 and folate are also frequent.\(^24–27\) Studies suggest that citizens of several European countries do not have adequate intakes of folic acid and B12 vitamins with respect to the recommendations.\(^28\) Besides inadequate intake, there are other factors that may cause B vitamins deficiency, such as malabsorption, drug–nutrient interactions, specific medical conditions, or increased requirements.\(^29\) Older people are more prone to have B vitamin deficiency, with the prevalence of vitamin B12 deficiency among older adult being estimated to
range between 10 and 38%, of folate between 29 and 35%, and of vitamin B6 between 24 and 31%. Hyperhomocysteinemia is a potential risk factor for several diseases. It has been associated with increased risk of neurodegenerative diseases (such as brain atrophy, cognitive impairment, and AD) and of cardiovascular diseases, amongst others. Low blood levels of folate and vitamin B12, and elevated tHcy levels have been associated with AD and vascular dementia: prospective studies in healthy older people have reported that individuals with tHcy concentrations >14 mmol/L had a two-fold higher risk of AD after adjustment for known risk factors. Distinct, not mutually exclusive, biological mechanisms could explain the connection between raised tHcy and cognitive impairment (such as regional brain atrophy, neuronal death, vascular mechanisms, neurofibrillary tangle and amyloid plaque formation, and epigenetic mechanism), being likely that several alternative pathways are involved. Recently, an international consensus on homocysteine and dementia concluded that raised tHcy is a strong modifiable risk factor for both cognitive decline, dementia and AD, conclusion which is supported by a large body of evidence. Normalization of laboratory vitamin status may be accomplished with oral vitamins, and there is evidence that supplements containing folate, vitamins B12, and/or B6, decrease homocysteine concentrations. Moreover, the international consensus recommended specific public health interventions, such as screening for raised tHcy in memory clinics or in people over 65 years old, and prescription of supplementary B vitamins to people who present raised tHcy, in order to avoid the risks of hyperhomocysteinemia.

The aim of this systematic review was to evaluate the impact on homocysteine levels of supplementation with vitamins B6, B12, and/or folic acid, specifically in patients with MCI.

2 | MATERIALS AND METHODS

2.1 | Research question and search strategy

A systematic search was conducted on July 2020 in EMBASE, MEDLINE®, PsycINFO, and Cochrane Central Register of Controlled Trials. The research question was...
formulated using the following Population, Intervention, Comparison, and Outcome (PICO) framework: in patients with MCI (P); what is the efficacy of vitamins B6, B12, and/or folic acid intake (I); compared with baseline values and/or compared with placebo or any other intervention (C); in reducing homocysteine levels from baseline (O).

Keywords and free text words used to search from the above-mentioned databases included: (mild cognitive impairment), (mild cognitive dysfunction), (mild cognition), (MCI), (incipient dementia), (early stage dementia), (B complex vitamins), (Vitamin B complex), (vitamin B6), (pyridoxine), (vitamin B9), (folate), (vitamin B12), (cobalamin). Detailed search string for Embase is provided in the supporting information (Table S1). Additional references were searched from the bibliography of selected systematic reviews and meta-analyses. There was no restriction on publication timeframe or language.

2.2 | Eligibility criteria

Articles were included if they followed pre-defined inclusion/exclusion criteria (Table S2). In particular, whenever the studies included mixed populations, such as patients with AD, they were only included if results were separately published for MCI.

2.3 | Review methodology

Abstracts identified during the search were reviewed by two independent researchers against pre-determined eligibility (inclusion/exclusion) criteria using the previously described PICO frame. Cases of uncertainty about the inclusion of a publication were resolved either through “reconciliation” (discussion between the two reviewers) or through “arbitration” by a third reviewer. Excluded publications were disregarded. After abstract review, full texts were reviewed by one researcher and checked by another, based on the eligibility criteria. The approach to resolving disagreements was the same as outlined above during the abstract review process. All papers included after the full text review were retained for data extraction. The inclusion and exclusion of studies are summarized in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

2.4 | Data extraction

A standardized extraction template on excel was developed to extract data from included publications. Data extracted were: population characteristics, clinical history, study design, and treatment details such as medication dose, frequency, composition, and duration. Measures included were mean, median, numbers with variables such as SD, SE, CI, and p-values.

The growth in homocysteine concentration was computed as the percentage increase between the mean homocysteine concentration reported at baseline and the one reported at the end of the intervention in each study. The mean homocysteine growth across identified studies was computed in a pooled analysis, by weighting the homocysteine growth from each single study by the respective population sample in the intervention arm.

2.5 | Assessment of the methodological quality of the studies

The quality of each study was assessed to ensure that the conclusions and findings of this review are based on the best available evidence and that any potential sources of bias in the data are identified. Eligible studies were assessed for bias using the Cochrane risk-of-bias version 2 (RoB 2) tool for randomized trials. For non-randomized controlled trials (RCTs), this review utilized the Brown and Black checklist to assess the quality of those studies.

The RoB 2 tool provides a framework for considering the risk of bias in the findings of any type of randomized trial. The tool is structured into five domains through which bias might be introduced into the results, namely: (a) bias arising from the randomization process; (b) bias due to deviations from intended interventions; (c) bias due to missing outcome data; (d) bias in measurement of the outcome; (e) bias in the selection of the reported result. The Brown and Black checklist considers the following possible biases: (a) reporting bias; (b) external validity bias; (c) internal validity—bias; (d) internal validity—confounding (selection bias); (e) power of the study.

3 | RESULTS

3.1 | Search results

The review identified a total of 457 citations after removal of duplicates. Following title and abstract review, 53 publications were retained for full-text review. During the full-text review, 41 were excluded due to the study design (n = 3), population (n = 6), intervention (n = 5), or outcomes (n = 26) not being of interest; thus, resulting in the inclusion of 12 publications, which correspond to 8 primary studies. The details of the selection process of articles are shown in Figure 2.
3.2 | Characteristics of the retrieved studies

Eight primary studies with 1,140 participants were included in the review. Four were RCTs, one was a quasi-controlled trial, and three were observational studies (Table 1). MCI patients sample sizes ranged from 16 to 279. Seven primary studies used the Mini-Mental State Examination (MMSE) as diagnostic criteria for inclusion, and one study did not report the diagnostic criteria, but was included since mean, minimum and maximum MMSE was reported and fit the MCI criteria (Table S3).

The mean age of included patients ranged from 68 years to 78 years, resulting in a mean (SD) of 74.1 (3.1) years for the B vitamins intervention groups. As for gender distribution, the mean (SD) percentage of females was 56.7% (10.3). Medical history was reported in five studies, of which all reported diabetes (range: 2.5% to 62.5%), and heart disease (range: 6.6% to 16.6%), four reported stroke (range: 7.8% to 22.2%), and three hypertension (range: 6.6% to 58.3%) (Table S4).

Mean (SD) length of the intervention period was 18.8 (19.3) months, with intervention period ranging from 1 to 60 months. Oral B vitamins supplementation was used in the included studies, with the following ingredients and dosage: all studies included folic acid in their intervention with a daily intake ranging from 400 to 30,000 μg/day; seven studies included vitamin B12, with a daily intake ranging from 25 to 2,000 μg/day; and four studies included vitamin B6, with a daily intake ranging from 20 to 300 mg/day (Table 1). One study did not report the dose of the intervention, but was included as it specified the combination of B vitamins which was used, which met this review criteria.

3.3 | Methodological quality of the studies

Three of the studies showed an overall high risk of bias measured by the RoB—in two studies, the high risk of bias was due to measurement of outcome, and, in the other, due to the selection of reported results. One study showed an overall low risk of bias. As for the quality of the observational studies and of the quasi-controlled trial—whose quality was assessed using the Downs and Black Quality checklist, based on the scores, one out of three included articles of observational studies and one quasi controlled study were categorized as fair and the remaining two were categorized as poor quality (Table 1).

3.4 | Impact of the interventions in homocysteine levels

The evaluation time point of homocysteine concentration levels (μmol/L) ranged from 1 month to 60 months.
after treatment. At baseline, mean homocysteine levels were above >15 mmol/L in the group B vitamin intervention arm in three studies, and between 10 and 15 mmol/L in five studies. All studies showed a statistically significant decrease in homocysteine levels in vitamin B group compared to the control group (Table 2).

In the B vitamins intervention groups, the decline of mean homocysteine concentration from baseline to the end of study ranged between 9.8% and 48.6%. The weighted mean growth across studies is −31.9% in the intervention arms versus 0.7% in the control arm.

Figure 3 displays the growth of mean homocysteine concentration per study in each of the reported evaluation time points, per type of intervention. A significant decline in homocysteine was observed as early as after 1 month of supplementation. Only two studies provided mean levels of homocysteine concentrations across time. Ma et al. reported a progressive decline through time (a 30.5% decline in mean homocysteine concentration was observed 6 months after treatment initiation, which increased to a 44.8% decline at 24 months of treatment). Kwok et al. report a 31.9% decline in mean homocysteine concentration at 12 months which is consistent with the decline observed at 24 months (32.6%).

The study which had a longer duration had the lowest decline in mean homocysteine concentration (9.8%). However, in this study, the data on folic acid and vitamin B12 supplementation was collected during a clinical interview at baseline and at the end of the 5 years observation period and includes patients who have used a combination of folic acid and vitamin B12 for more than a year, but not necessarily throughout the whole period, nor at a prespecified dose.

The highest decline in homocysteine concentration is observed in the combination of vitamins B6, B12, and folic acid. Overall, the highest declines in homocysteine concentrations were observed in some combination of vitamins B6, B12, and/or folic acid. Ma et al. reported a higher decline in homocysteine when using a combination of folic acid and vitamin B12 (33.0%) than when using either supplements alone (25.0% with folic acid and 23.4% with vitamin B12).

### 3.5 Impact of the interventions in B vitamin levels

#### 3.5.1 Folate

Folate levels (ng/mL) were reported in seven studies. All studies showed statistically significant increase in
| Author and year | Intervention/comparator | n   | Time point | Homocysteine concentrations (μmol/L) | % change to baseline | p-value |
|-----------------|-------------------------|-----|------------|--------------------------------------|----------------------|---------|
| Kwok (2020)52   | Vitamin B12 + folic acid | 138 | Baseline   | Mean (SD): 13.8 (3.4)                | —                    | NR      |
|                 | Placebo                 | 141 |           | Mean (SD): 13.8 (3)                  | —                    |         |
|                 | Vitamin B12 + folic acid| 121 | 12 months  | Mean (SD): 9.4 (2.2)                 | -31.9%               | <.0001  |
|                 | Placebo                 | 125 |           | Mean (SD): 13.5 (3.6)                | -2.2%                | NR      |
|                 | Vitamin B12 + folic acid| 118 | 24 months  | Mean (SD): 9.3 (2.4)                 | -32.6%               | <.0001  |
| Ma (2019)17     | Folic acid alone        | 60  | Baseline   | Mean (SD): 19.88 (1.93)              | —                    | NR      |
|                 | Vitamin B12 alone       | 60  |           | Mean (SD): 20.99 (1.1)               | —                    |         |
|                 | Vitamin B12 + folic acid| 60  |           | Mean (SD): 21.98 (1.71)              | —                    |         |
|                 | Control                 | 60  |           | Mean (SD): 19.22 (1.66)              | —                    |         |
|                 | Folic acid alone        | 60  | 6 months   | Mean (SD): 14.91 (0.35)              | -25.0%               | .027    |
|                 | Vitamin B12 alone       | 60  |           | Mean (SD): 16.07 (0.64)              | -23.4%               | .017    |
|                 | Vitamin B12 + folic acid| 60  |           | Mean (SD): 14.72 (0.39)              | -33.0%               | .012    |
|                 | Control                 | 60  |           | Mean (SD): 18.21 (0.67)              | -5.3%                | NR      |
| Ma (2019)19     | Folic acid supplementation | 90 | Baseline   | Mean (SD): 13.65 (4.82)              | —                    | NR      |
|                 | Control                 | 90  |           | Mean (SD): 12.19 (3.85)              | —                    |         |
|                 | Folic acid supplementation | 90 | 6 months   | Mean (SD): 9.49 (5.72)               | -30.5%               | NR      |
|                 | Control                 | 90  | 12 months  | Mean (SD): 10.97 (2.42)              | -10.0%               |         |
|                 | Folic acid supplementation | 90 | 18 months  | Mean (SD): 8.21 (1.22)               | -39.9%               | NR      |
|                 | Control                 | 90  | 24 months  | Mean (SD): 11.33 (1.51)              | -7.1%                |         |
|                 | Folic acid supplementation | 90 |           | Mean (SD): 11.36 (1.49)              | -6.8%                |         |
|                 | Control                 | 90  |           | Mean (SD): 7.54 (1.33)               | -44.8%               | .028    |
|                 | Folic acid supplementation | 90 |           | Mean (SD): 11.37 (1.21)              | -6.7%                | NR      |
| Lee (2016)18    | Vitamin B6, B12, and folic acid | 24 | Baseline   | Mean (SD): 19.29 (7.09)              | —                    | NR      |
|                 | Control                 | 24  |           | Mean (SD): 17.57 (5.4)               | —                    |         |
|                 | Vitamin B6, B12, and folic acid | 24 | 3 months   | Mean (SD): 10.92 (1.67)              | -43.4%               | .001    |
|                 | Control                 | 24  |           | Mean (SD): 19.08 (5.57)              | 8.6%                 | NR      |
| Blasko (2012)56 | Non user                | 51  | Baseline   | Mean (SD): 15 (4.7)                  | —                    | NR      |
|                 | Inconsistent users      | 20  |           | Mean (SD): 14 (4.4)                  | —                    |         |
|                 | Combination users       | 10  |           | Mean (SD): 12.3 (2.5)                | —                    |         |
|                 | Non user                | 51  | 60 months  | Mean (SD): 15.2 (6.3)                | 1.3%                 | NR      |
|                 | Inconsistent users      | 20  |           | Mean (SD): 12.7 (4.7)                | -9.3%                | .044    |
|                 | Combination users       | 10  |           | Mean (SD): 11.1 (1.6)                | -9.8%                | .007    |
| De Jager (2012)53| Vitamin B6, B12, and folic acid | 110| Baseline   | Mean (95%CI): 11.3 (10.7–11.9)       | —                    | NR      |
|                 | Placebo                 | 113 |           | Mean (95%CI): 11.6 (10.9–12.9)       | —                    |         |
3.5.1 | Vitamin B6

Vitamin B6 (mg/d) was assessed in five studies. Three studies showed a statistically significant increase in vitamin B6 levels in the treatment group compared to the control group. The weighted mean change across the four studies with vitamin B6 supplementation in the intervention is 33.6% in the intervention arms versus 1.2% in the control arm.

3.5.2 | Vitamin B12

Vitamin B12 levels (pg/mL) were reported in seven studies. Four studies showed a statistically significant increase in vitamin B12 levels in the treatment group compared to the control group. The weighted mean change across the six studies with vitamin B12 supplementation in the intervention is 65.6% in the intervention arms versus 2.1% in the control arm.
3.5.3 | Vitamin B₆

Although four studies included vitamin B₆ in their intervention, none of them has reported the vitamin B₆ levels of their population, neither at baseline nor at the end of the intervention.

4 | DISCUSSION

This systematic literature review, which included results from 1,140 patients from eight primary studies, has identified consistent evidence of a statistically significant decrease in homocysteine concentration in MCI patients treated with vitamins B₆, B₁₂, and/or folic acid compared to the control groups, with a mean decline in homocysteine of 31.9%. Results are aligned with those from Clarke et al., whom, in a meta-analysis from 11 trials, not specific to MCI, found that allocation to B vitamins was associated with a 26.1–28.4% reduction in plasma concentrations of homocysteine, including patients with distinct cognitive status.³⁶ In our review, the mean age of included patients was 74.1 years old across studies, whereas patients included in Clarke et al. review were younger (68 years old in the cognitive-domain trials and 66 years old in the global cognition trials). The highest tHcy reduction reported in Clarke et al. was 34.9% and the lowest 12.4%,³⁶ while in the present review it ranged between 9.8%³⁵ and 48.6%.³² The decline in homocysteine levels was higher than the maximum reported by Clarke et al. in three of the studies.¹⁸,¹⁹,³²

Clinically relevant and statistically significant results were observed in all studies, irrespective of the duration of the intervention. The studies reporting the highest homocysteine-lowering effects have used a combination of vitamins B₆, B₁₂, and/or folic acid, and one study specifically reports higher results when using a combination of folic acid and vitamin B₁₂, than when using either ingredients alone.¹⁷ As previously mentioned, the mechanisms behind the connection between raised homocysteine levels, vitamins B₆, B₁₂, and/or folic acid levels and cognitive impairment are various and not mutually exclusive.³⁹ Homocysteine metabolism may occur through three pathways: (a) the homocysteine remethylation to form methionine catalyzed by the methionine synthase (MTR) enzyme (a vitamin B₁₂ and folate-dependent reaction); (b) the transsulfuration pathway, through which homocysteine is converted to cystathionine by cystathionine β-synthase (CBS); and by (c) homocysteine remethylation to methionine via betaine-homocysteine methyltransferase (BHMT).¹⁵,⁵⁶

Vitamin B₆ is thought to activate the transsulfuration pathway, potentially leading to lower Hcy levels.⁵⁷ In this metabolic pathway—fundamental to maintain optimal cellular function—sulfur is transferred from homocysteine to cysteine⁵⁸ which can be used to form GSH and enhancing the antioxidant defenses of the organism. Nonetheless, as there is a significant heterogeneity in the ingredients, dosage, and duration of the intervention across studies, no specific conclusion can be drawn as to the most effective treatment duration, combination and dosage of vitamins B₆, B₁₂, and/or folic acid supplementation to achieve an optimal homocysteine-lowering effect. This limitation was also identified in a previous review analyzing the benefits of B vitamins on cognitive function.⁶⁰

The present review has focused on the impact of supplementations with vitamins B₆, B₁₂, and/or folic acid on the reduction of homocysteine levels, as this reduction might be associated with benefits for cognition. The research question was not extended to the direct association between supplementations with vitamins B₆, B₁₂, and/or folic acid and cognitive status due to the heterogeneity of tests used to assess cognitive function in these studies (Table S6). Future high-quality studies with homogenous evaluations of cognitive function are required to enable a robust assessment of the relation between supplementation with vitamins B₆, B₁₂, and/or folic acid and cognitive function in MCI patients.

5 | CONCLUSIONS

The present systematic review corroborates the beneficial effect of supplementation with vitamins B₆, B₁₂, and/or folic acid on reducing homocysteine levels in MCI patients, from as early as 1 month. The differences in controls are significant and clinically relevant, supporting a potential use of these supplements as a strategy to compensate low levels of these vitamins and reduce the risk of hyperhomocysteinemia.

ACKNOWLEDGMENTS

The authors would like to thank David Gasche (IQVIA, Spain), Mafalda Carmo (IQVIA, Spain), Marta Rubio (IQVIA, Spain) for support in the systematic literature review, as independent reviewers, and for support in the medical writing. The study was funded by grants from Nestlé Health Science, Switzerland.

CONFLICT OF INTEREST

Dr Olaso, Dr Bellelli, Dr Morandi, Dr Inzitari, and Dr Viña received personal fees from Nestlé Health Science. Núria Barcons is a Nestlé Health Science employee.

ORCID

José Viña https://orcid.org/0000-0001-9709-0089
ENDNOTE
* Mild cognitive dysfunction was used in the search strategy as it is a MeSH term.

REFERENCES
1. Cunnane SC, Trushina E, Morland C, et al. Brain energy rescue: An emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19:609–633.
2. Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: A clinical perspective. Mayo Clin Proc. 2014;89: 1452–1459.
3. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:126–135.
4. Tampi RR, Tampi DJ, Chandran S, Ghori A, Durning M. Mild cognitive impairment: A comprehensive review. Healthy Aging Res. 2015;4:39.
5. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia—Meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119: 252–265.
6. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–1992.
7. Praticò D, Clark CM, Liun F, Lee VY-M, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch Neurol. 2002;59:972–976.
8. Krinsky NI. Mechanism of action of biological antioxidants. Proc Soc Exp Biol Med. 1992;200:248–254.
9. Viña J, Hems R, Krebs HA. Maintenance of glutathione content is isolated hepatocytes. Biochem J. 1978;170:627–630.
10. Miller J.W. (2013) Homocysteine. In: Encyclopedia of human nutrition (3rd ed.) (Caballero, B., ed), pp. 424-430. Waltham, MA: Academic Press.
11. Saez G, Thornalley PJ, Hill HA, Hems R, Bannister JV. The effect of cysteine oxidation on isolated rat hepatocytes. Biochim Biophys Acta. 1982;719:24–31.
12. Viña J, Saez GT, Wiggins D, Roberts AFC, Hems R, Krebs HA. The effect of cysteine oxidation on isolated hepatocytes. Bioch J. 1983;212:39–44.
13. Munday R. Toxicity of thiols and disulphides: Involvement of free-radical species. Free Radic Biol Med. 1989;7:659–673.
14. American Society of Human Genetics/American College of Medical Genetics Test and Technology Transfer Committee Working Group. Measurement and Use of Total Plasma Homocysteine. Am J Hum Genet. 1998;63:1541–1543.
15. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med. 2009;60:39–54.
16. Agarwal R. Vitamin B12 deficiency & cognitive impairment in elderly population. Indian J Med Res. 2011;134:410–412.
17. Ma F, Zhou X, Li Q, et al. Effects of folic acid and vitamin B12, alone and in combination on cognitive function and inflammatory factors in the elderly with mild cognitive impairment: A single-blind experimental design. Curr Alzheimer Res. 2019;16: 622–632.
18. Lee HK, Kim SY, Sok SR. Effects of multivitamin supplements on cognitive function, serum homocysteine level, and depression of Korean older adults with mild cognitive impairment in care facilities. J Nurs Scholarsh. 2016;48:223–231.
19. Ma F, Li Q, Zhou X, et al. Effects of folic acid supplementation on cognitive function and Ap-related biomarkers in mild cognitive impairment: A randomized controlled trial. Eur J Nutr. 2019;58:345–356.
20. Gillette-Guyonnet S, Secher M, Vellas B. Nutrition and neurodegeneration: Epidemiological evidence and challenges for future research. Br J Clin Pharmacol. 2013;75:738–755.
21. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55: 1449–1455.
22. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteine in an elderly population. JAMA. 1993;270:2693–2698.
23. Nygård Ø, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 1995;274:1526–1533.
24. Gonzalez-Gross M, Sola R, Albers U, et al. B-vitamins and homocysteine in Spanish institutionalized elderly. Int J Vitam Nutr Res. 2007;77:22–33.
25. Eussen SJ, de Groot LC, Joosten LW, et al. Effect of oral vitamin B12 with or without folic acid on cognitive function in older people with mild vitamin B12 deficiency: A randomized, placebo-controlled trial. Am J Clin Nutr. 2006;84:361–370.
26. Lewerin C, Matousek M, Steen G, Johansson B, Steen B, Nilsson-Ehle H. Significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: A placebo-controlled randomized study. Am J Clin Nutr. 2005;81:1155–1162.
27. Janson JJ, Galarza CR, Murúa A, et al. Prevalence of hyperhomocysteinemia in an elderly population. Am J Hypertens. 2002;15:394–397.
28. Dhonukshe-Rutten RA, de Vries JH, de Bree A, van der Put N, van Staveren WA, de Groot LC. Dietary intake and status of folate and vitamin B12 and their association with homocysteine and cardiovascular disease in European populations. Eur J Clin Nutr. 2009;63:18–30.
29. Porter K, Hoey L, Hughes CF, Ward M, McNulty H. Causes, consequences and public health implications of low B-vitamin status in ageing. Nutrients. 2016;8:725.
30. Hoey L, Strain J, McNulty H. Studies of biomarker responses to intervention with vitamin B-12: A systematic review of randomized controlled trials. Am J Clin Nutr. 2009;89:1981S–1996S.
31. Gupta J, Mujwar S, Varshney K, Varshney M. Hyperhomocysteinemia: A silent hassle for human beings, allied complications and pragmatic strategies. Int J Pharm Sci Res. 2019;10:5294–5301.
32. Lehma M, Regland B, Blennow K, Gottfries CG. Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement Geriatr Cogn Disord. 2003;16:145–150.
33. Jakubowski H. Pathophysiologial consequences of homocysteine excess. J Nutr. 2006;136:1741S–1749S.
34. Sachdev PS. Homocysteine and brain atrophy. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1152–1161.
35. Blasko I, Hinterberger M, Kemmler G, et al. Conversion from mild cognitive impairment to dementia: Influence of folic acid and vitamin B12 use in the vita cohort. J Nutr Health Aging. 2012;16:687–694.
36. Clarke R, Bennett D, Parish S, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: Meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr. 2014;100:657–666.
37. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476–483.
38. Kivipelto M, Annerbo S, Hultdin J, et al. Homocysteine and homocysteine to holotranscobalamin and the risk of dementia and Alzheimer's disease: A prospective study. Eur J Neurol. 2009;16:808–813.
39. Smith AD, Refsum H, Bottiglieri T, et al. Homocysteine and dementia: An international consensus statement. J Alzheimers Dis. 2018;62:561–570.
40. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006;354:2764–2772.
41. Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr. 2000;71:614S–620S.
42. Clarke R, Birks J, Nexo E, et al. Low vitamin B-12 status and risk of cognitive decline in older adults. Am J Clin Nutr. 2007;86:1384–1391.
43. Clarke R. B-vitamins and prevention of dementia. Proc Nutr Soc. 2008;67:75–81.
44. McCaddon A, Hudson P, Davies G, Hughes A, Williams JHH, Wilkinson C. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord. 2001;12:309–313.
45. Price BR, Wilcock DM, Weekman EM. Hyperhomocysteinemia as a risk factor for vascular contributions to cognitive impairment and dementia. Front Aging Neurosci. 2018;10:350–350.
46. Collaboration H.L.T. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ. 1998;316:894–898.
47. Sackett DL. Evidence-based medicine. Semin Perinatol. 1997;21:3–5.
48. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6:e1000097.
49. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from https://www.training.cochrane.org/handbook.
50. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed December, 2020.
51. Frick B, Gruber B, Schroechsnadel K, Leblhuber F, Fuchs D. Homocysteine but not neopterin declines in demented patients on B vitamins. J Neural Transm. 2006;113:1815–1819.
52. Kwok T, Wu Y, Lee J, et al. A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients. Clin Nutr. 2020;39:2399–2405.
53. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial. Int J Geriatr Psychiatry. 2012;27:592–600.
54. Schroechsnadel K, Gruber B, Frick B, et al. Long-term supplementation with B vitamins does not change plasma neopterin concentrations in demented patients. Pteridines. 2006;17:135–144.
55. Lee J-H, Ahn S-Y, Lee HA, et al. Dietary intake of pantothenic acid is associated with cerebral amyloid burden in patients with cognitive impairment. Food Nutr Res. 2018:62:1415.
56. Blom HI, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J Inherit Metab Dis. 2011;34:75–81.
57. Taysi S, Keles MS, Gumustekin K, et al. Plasma homocysteine and liver tissue S-adenosylmethionine, S-adenosylhomocysteine status in vitamin B6-deficient rats. Eur Rev Med Pharmacol Sci. 2015;19:154–160.
58. Sbodio JI, Snyder SH, Paul BD. Regulators of the transsulfuration pathway. Br J Pharmacol. 2019;176:583–593.
59. Hsu C-C, Cheng C-H, Hsu C-L, Lee W-J, Huang S-C, Huang Y-C. Role of vitamin B6 status on antioxidant defenses, glutathione, and related enzyme activities in mice with homocysteine-induced oxidative stress. Food Nutr Res. 2015;59:25702–25702.
60. Suh SW, Kim HS, Han JH, et al. Efficacy of vitamins on cognitive function of non-demented people: A systematic review and meta-analysis. Nutrients. 2020;12:1168.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article**: Olaso-Gonzalez G, Inzitari M, Bellelli G, Morandi A, Barcons N, Viña J. Impact of supplementation with vitamins B6, B12, and/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impairment: A systematic review. IUBMB Life. 2021;1–11. https://doi.org/10.1002/iub.2507